Enanta Pharmaceuticals combines a perfect earnings beat streak and positive momentum with leverage concerns, negative news sentiment, and a narrow miss on the engine's risk/reward gate.
Thesis pillars
- Fcf Positive Despite Gaap Loss—
- Perfect Earnings Beat Streak—
- Leverage Penalty Negative Sentiment—
- +2 more pillars — see the Why tab for full reasoning
Enanta Pharmaceuticals, Inc. (ENTA) Stock Analysis
Range Bound setup · Inst Constrain edge
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $13.16, but acceptable to hold if already in. Reasons: Concentration risk — Counterparty: AbbVie; Market cap $383M below $400M minimum.
Enanta Pharmaceuticals is a biotechnology company using its chemistry-driven drug discovery platform to develop small-molecule treatments for virology (RSV, SARS-CoV-2, Hepatitis B) and immunology (KIT and STAT6 inhibitors for urticaria, atopic dermatitis, and related type-2... Read more
Hold if already holding. Not a fresh buy at $13.16, but acceptable to hold if already in. Reasons: Concentration risk — Counterparty: AbbVie; Market cap $383M below $400M minimum. Chart setup: RSI 57 mid-range, Bollinger mid-band. Market cap $383M below $400M minimum. Not in investable universe. Score 4.6/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 91d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Enanta Pharmaceuticals, Inc.
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals earns substantially all of its royalty revenue from AbbVie's sales of MAVYRET/MAVIRET, an HCV combination therapy built on Enanta-discovered glecaprevir that gained FDA approval as the first acute-HCV treatment in June 2025, while advancing wholly-owned clinical programs in RSV (zelicapavir, EDP-323) and preclinical immunology candidates (EDP-978, EPS-3903) targeting urticaria and atopic dermatitis. The company held $188.9 million in cash and short-term marketable securities as of September 30, 2025.
Enanta's royalty stream is capped and shared: it earns annually tiered, double-digit per-product royalties on 50% of MAVYRET/MAVIRET's calendar-year net sales, but sold 54.5% of those future royalties to an OMERS affiliate in April 2023 for $200.0 million upfront, subject to a repayment cap of 1.42 times that purchase price. On the pipeline side, zelicapavir, an RSV N-protein inhibitor with FDA Fast Track designation, reported positive Phase 2b results in high-risk adults in September 2025, showing a 2.2-to-6.7-day faster symptom resolution and a lower hospitalization rate (1.7% vs. 5.0% on placebo) versus placebo; a second RSV candidate, EDP-323, targets the L-protein and completed a Phase 2a challenge study. Enanta's immunology pipeline targets KIT (EDP-978, IND planned first quarter 2026) and STAT6 (EPS-3903, IND planned second half 2026) mechanisms for chronic spontaneous urticaria and atopic dermatitis, both preclinical.
Show full overview
Enanta's near-term financial health rides almost entirely on a drug it no longer controls: the 10-K states that revenues for the next several years are substantially dependent upon AbbVie's continued success selling MAVYRET/MAVIRET, and that declining HCV diagnosis and treatment rates could reduce AbbVie's sales volumes in future quarters. Because Enanta's own RSV and immunology candidates remain pre-revenue — with zelicapavir needing a larger pivotal study to confirm its Phase 2b signal and the KIT and STAT6 programs still preclinical — any AbbVie-driven royalty decline would fall directly on Enanta's operating cash flow with no offsetting commercial revenue elsewhere in the business.
From Enanta Pharmaceuticals, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-08-17Recent Developments — Enanta Pharmaceuticals, Inc.
Latest news
- NEWS Enanta Pharma Q3 EPS $(0.67) Misses $(0.54) Estimate, Sales $14.359M Miss $16.796M Estimate — benzinga Aug 10, 2026
Generated 2026-08-17T14:17:25Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHcounterpartyAbbVie10-K Item 1: 'Since August 2017, substantially all of our royalty revenue has been derived from AbbVie's net sales of MAVYRET/MAVIRET.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Revenue shrinking — -21.6% YoY. Growth thesis broken unless recovery story develops.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -96.9%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $13.16, but acceptable to hold if already in. Reasons: Concentration risk — Counterparty: AbbVie; Market cap $383M below $400M minimum. Chart setup: RSI 57 mid-range, Bollinger mid-band. Market cap $383M below $400M minimum. Not in investable universe. Target $18.42 (+40.0%), stop $12.24 (−7.5%), A.R:R 4.7:1. Score 4.6/10, moderate confidence.
Take-profit target: $18.42 (+39.9% upside). Target $18.42 (+40.0%), stop $12.24 (−7.5%), A.R:R 4.7:1. Stop-loss: $12.24.
Concentration risk — Counterparty: AbbVie; Market cap $383M below $400M minimum.
Enanta Pharmaceuticals, Inc. trades at a P/E of N/A (forward -6.2). TrendMatrix value score: 7.9/10. Verdict: Hold.
12 analysts cover ENTA with a consensus score of 4.3/5. Average price target: $21.
What does Enanta Pharmaceuticals, Inc. do?Enanta Pharmaceuticals is a biotechnology company using its chemistry-driven drug discovery platform to develop...
Enanta Pharmaceuticals is a biotechnology company using its chemistry-driven drug discovery platform to develop small-molecule treatments for virology (RSV, SARS-CoV-2, Hepatitis B) and immunology (KIT and STAT6 inhibitors for urticaria, atopic dermatitis, and related type-2 inflammatory diseases). The company earns royalty revenue from AbbVie's sales of MAVYRET/MAVIRET, an HCV combination therapy containing Enanta-discovered glecaprevir, and had $188.9 million in cash and short-term marketable securities as of September 30, 2025, expected to fund operations into fiscal 2029.